News

News

Press releases

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets

Twitter

@KynTherapeutics
Did you know that the tumor microenvironment (TME) is an incredibly important space for cancer drug development? Re… http://HK98fRBVlT

@KynTherapeutics
Great recent high-level review in @biocentury of the state-of-play in immuno-metabolism at:… http://5AsCOE985q

@KynTherapeutics
We're proud to support and showcase work by local artists Estelle Disch and Nancy Beams, members of… http://dlS09K71Li

@KynTherapeutics
Kyn advisor and immunotherapy expert Dr. Pawel Kalinski speaks today on COX2-PGE2-mediated immunosuppression in tum… http://LVi3kIWGZY

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn